Table 3.

Characteristics of patients treated with MBRT.

Age	Location	Histological subtype	Genomic alteration	MBRT initiated	Clinical trial	PFS (m)	Best response	OS (m)
57	Limbs	Leiomyosarcoma	AKT2 amplification	Everolimus	MOST	2.6	Progression	10.9
47	Trunk	MPNST	ERBB2 mutation c.G2329T/p.V777L	Lapatinib	MOST	1.9	Stable	3.8
79	Limbs	Angiosarcoma	FLT4 amplification	Pazopanib	MOST	3.1	Partial response	10.7
30	Limbs	UPS	AKT2 19q13.1-q13.2 deletion	Everolimus	–	1.4	Progression	4.1
13	Limbs	Osteosarcoma	KDR amplification	Regorafenib	BAY15906 Phase I	1.9	Progression	3.1
20	Limbs	Osteosarcoma	VEGFA amplification	Sorafenib	–	2.3	Progression	2.8
21	Limbs	Osteosarcoma	PIK3CA amplification	Everolimus	MOST	2.7	Progression	11
43	Trunk	Osteosarcoma	CDK4 amplification	Ribociclib	LEE011 Phase I	1.7	Progression	6.1
31	Limbs	Ewing sarcoma	TIE1 mutation c.G1379C/p.S460T	Sorafenib	–	3.6	Stable	7.4
58	Limbs	Chondrosarcoma	KDR mutation c.3380C>A	Sorafenib	–	33.6	Stable	39.6
58	Abdominal	GIST	CDKN2A homozygous deletion	Palbociclib	–	0.8	Progression	4.9
66	Abdominal	GIST	CDKN2A homozygous deletion	Palbociclib	CycliGIST	0.9	Progression	2.6
80	Abdominal	GIST	CDKN2A homozygous deletion	Palbociclib	CycliGIST	3.7	Stable	22.9